Repurposing ALK inhibitors as influenza and corona virus antivirals targeting lymphocyte tyrosine kinase (LTK)
Elias Tjärnhage, Thea Kristin Våtsveen, Melinda Raki, David Nemazee, Hesso Farhan, Ludvig Munthe, Gunnveig Grodeland · 2026
Read Repurposing ALK inhibitors as influenza and corona virus antivirals targeting lymphocyte tyrosine kinase (LTK) by Elias Tjärnhage, Thea Kristin Våtsveen, Melinda Raki, David Nemazee, Hesso Farhan, Ludvig Munthe, Gunnveig Grodeland (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13279203.txt.
Description
Elias Tjärnhage and colleagues published a 2026 study testing whether cancer drugs that block ALK-family kinases can be repurposed as antivirals against influenza and coronaviruses. Their target is LTK, a kinase that sits in the endoplasmic reticulum and controls how proteins are packaged for secretion from the cell. Because viruses depend on that same shipping machinery to build and release new particles, blocking it attacks the host rather than the virus, which should make escape mutations less likely.
The team evaluated repurposed inhibitors in cell cultures and in mice, and reports that dampening protein secretion reduced viral infection in both settings. Host-directed drugs could serve as a first line of defense when a new virus emerges and vaccines do not yet exist. The approach may matter most for elderly and immunocompromised people, who respond poorly to vaccines and suffer the worst outcomes from respiratory infections.
Catalog record
| CREATOR | Elias Tjärnhage, Thea Kristin Våtsveen, Melinda Raki, David Nemazee, Hesso Farhan, Ludvig Munthe, Gunnveig Grodeland |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 17 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |